Table 1.
Baseline clinical characteristics (N = 59).
| Variable | Value |
|---|---|
| Age, y | 71.0 ± 11.2 |
| Gender (M/F) | 39/20 |
| Comorbidities | |
| Smoker, n (%) | 26 (44.1) |
| Diabetes mellitus, n (%) | 27 (45.8) |
| Hypertension, n (%) | 40 (67.8) |
| Hypercholesterolemia, n (%) | 35 (59.3) |
| Coronary artery disease, n (%) | 17 (28.8) |
| Cerebrovascular disease, n (%) | 6 (10.2) |
| Renal impairment, n (%) | 8 (13.6) |
| Dialysis, n (%) | 2 (3.4) |
| Obesity, n (%) | 11 (18.6) |
| Cardiopathy, n (%) | 13 (22.0) |
| Patency of stenting (month) | 13.2 ± 9.1 |
| Number of stents | 1.9 ± 0.6 |
| Size of stents (mm) | 5.1 ± 0.3 |
| Antiplatelet treatment before restenosis, n (%) | |
| Aspirin 100mg per day | 55 (93.2) |
| Stop medication due to bleeding | 4 (6.8) |
| Onset of ischemia (day) | 46.4 ± 17.3 |
| Rutherford classification, n (%) | |
| 0–1 | 0 |
| 2–3 | 11 (18.6) |
| 4–6 | 48 (81.4) |
| TASC classification | |
| A | 4 (6.8) |
| B | 8 (13.6) |
| C | 16 (27.1) |
| D | 31 (52.5) |
| In-stent lesion length (cm) | 18.4 ± 7.8 |
| Mehran's classification of ISRs, n (%) | |
| I | 4 (6.8%) |
| II | 3 (5.1) |
| III | 10 (16.9) |
| IV | 42 (71.2) |
| GLASS classification for CLI | |
| I | 12 (20.3) |
| II | 25 (42.3) |
| III | 22 (37.4) |
| Critical limb ischemia | 49 (83.1) |
| Number of runoff vessels, n (%) | |
| 1 | 34 (57.6) |
| 2 | 17 (28.8) |
| 3 | 8 (13.6) |
| Thrombus detected by CDU, n (%) | 40 (67.8) |
| Target vessel diameter (mm) | 4.88 ± 7.86 |
| ABI | 0.38 ± 0.10 |
CDU, color duplex ultrasonography; TLR, target lesion revascularization; ISR, in-stent restenosis; TASC, TransAtlantic Inter-Society Consensus; GLASS, Global Limb Anatomic Staging System; ABI, ankle/brachial index.